4.6 Article

AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes in vivo resistance to PD-L1-immunotherapy

Journal

AMERICAN JOURNAL OF CANCER RESEARCH
Volume 12, Issue 7, Pages 3141-3147

Publisher

E-CENTURY PUBLISHING CORP

Keywords

Checkpoint inhibitor blockade; PD-L1; CTLA-4; oncolytic virotherapy; oncolytic adenovirus; TGF-beta; BETA PRIME (NCT04673942)

Categories

Ask authors/readers for more resources

Monoclonal antibodies targeting PD-1/PD-L1 and CTLA-4 have revolutionized the treatment of various cancers. However, resistance to these inhibitors is a major challenge. This study evaluated a combination therapy using an oncolytic adenovirus and PD-L1 blockade, which showed potential in reversing PD-L1 resistance.
Monoclonal antibodies targeting the programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) axes have permanently changed the therapeutic landscape for multiple tumor types previously associated with a dismal prognosis such as melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer, head and neck squamous cell carcinoma, MSI-high colorectal carcinoma, Merkel cell carcinoma, and Hodgkin lymphoma. However, only a subset of patients initially benefits from these inhibitors, and increasing clinical experience indicates that in a substantial proportion of initial responders, lethal secondary resistance ultimately develops months or years later. In this paper we evaluated combination therapy with a Phase 1 oncolytic adenovirus called AdAPT-001, armed with a TGF-beta trap that binds to and neutralizes the immunosuppressive cytokine, TGF-beta, and a checkpoint inhibitor, anti-PD-L1, in PD-L1 resistant tumors. The study, which was performed in an immunocompetent syngeneic ADS-12 mouse model, demonstrated that the combination of AdAPT-001 with PD-L1 blockade reversed PD-L1 resistance, potentially representing a future paradigm shift for patients that are primarily or secondarily resistant to checkpoint inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available